Clinical and pre-clinical utility of genomics in medulloblastoma

References

• Ostrom QT, De Blank PM, Kruchko C, et al. Alex’s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. Neuro Oncol. 2015;16 Suppl 10:x1–x36.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Taylor MD. Medulloblastoma: from Myth to Molecular. J Clin Oncol. 2017;35:2355–2363.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children’s Cancer Group Study. J Clin Oncol. 1999;17:2127–2136.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–4208.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81:690–698.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–820.
   PubMed Web of Science ®Google Scholar
• Lannering B, Rutkowski S, Doz F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol. 2012;30:3187–3193.
   PubMed Web of Science ®Google Scholar
• Kortmann RD, Kuhl J, Timmermann B, et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT ‘91. Int J Radiat Oncol Biol Phys. 2000;46:269–279.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821–831.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012;12:818–834.
   PubMed Web of Science ®Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473–484.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465–472.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–820.
   PubMed Web of Science ®Google Scholar
• Cavalli FMG, Remke M, Rampasek L, et al. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017;31:737–54.e736.
   PubMed Web of Science ®Google Scholar
• Schwalbe EC, Lindsey JC, Nakjang S, et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 2017;18:958–971.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Buchhalter I, Morrissy AS, et al. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547:311–317.
   PubMed Web of Science ®Google Scholar
• Zhukova N, Ramaswamy V, Remke M, et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013;31:2927–2935.
   PubMed Web of Science ®Google Scholar
• Waszak SM, Northcott PA, Buchhalter I, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018;19:785–798.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200–1207.
   PubMed Web of Science ®Google Scholar
• Hill RM, Kuijper S, Lindsey JC, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015;27:72–84.
   PubMed Web of Science ®Google Scholar
• Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129:515–524.
   PubMed Web of Science ®Google Scholar
• Pietsch T, Schmidt R, Remke M, et al. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol. 2014;128:137–149.
   PubMed Web of Science ®Google Scholar
• Gottardo NG, Hansford JR, McGlade JP, et al. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014;127:189–201.
   PubMed Web of Science ®Google Scholar
• Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25:393–405.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Triscott J, Northcott PA, et al. Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. J Clin Oncol. 2015;33:e27–31.
   PubMed Web of Science ®Google Scholar
• Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013;126:917–929.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012;488:49–56.
   PubMed Web of Science ®Google Scholar
• Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol. 2014;32:4155–4161.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Sahm F, Stichel D, et al. Molecular characterization of medulloblastomas with extensive nodularity (MBEN). Acta Neuropathol. 2018. DOI:10.1007/s00401-018-1840-0. Epub ahead of print.
   Web of Science ®Google Scholar
• Guerrini-Rousseau L, Dufour C, Varlet P, et al. Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk and prognosis. Neuro Oncol. 2017;20:1122–1132.
   Web of Science ®Google Scholar
• Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010;468:1095–1099.
   PubMed Web of Science ®Google Scholar
• Perreault S, Ramaswamy V, Achrol AS, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2014;35:1263–1269.
   PubMed Web of Science ®Google Scholar
• Mata-Mbemba D, Zapotocky M, Laughlin S, et al. MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. AJNR Am J Neuroradiol. 2018;39:949–955.
   PubMed Web of Science ®Google Scholar
• Wefers AK, Warmuth-Metz M, Poschl J, et al. Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol. 2014;127:931–933.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Adamski J, et al. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol. 2016;18:291–297.
   PubMed Web of Science ®Google Scholar
• Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016;18:982–990.
   PubMed Web of Science ®Google Scholar
• Mazloom A, Zangeneh AH, Paulino AC. Prognostic factors after extraneural metastasis of medulloblastoma. Int J Radiat Oncol Biol Phys. 2010;78:72–78.
   PubMed Web of Science ®Google Scholar
• Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32:886–896.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Nor C, Taylor MD. p53 and Meduloblastoma. Cold Spring Harb Perspect Med. 2016;6:a026278.
   Web of Science ®Google Scholar
• Robinson GW, Rudneva VA, Buchhalter I, et al. Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncol. 2018;19:768–784.
   PubMed Web of Science ®Google Scholar
• Robinson GW, Orr BA, Wu G, et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33:2646–2654.
   PubMed Web of Science ®Google Scholar
• Kieran MW, Chisholm J, Casanova M, et al. Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. Neuro Oncol. 2017;19:1542–1552.
   PubMed Web of Science ®Google Scholar
• Robinson GW, Kaste SC, Chemaitilly W, et al. Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor. Oncotarget. 2017;8:69295–69302.
   PubMedGoogle Scholar
• Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants. J Clin Oncol. 2011;29:1408–1414.
   PubMed Web of Science ®Google Scholar
• Remke M, Hielscher T, Korshunov A, et al. FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. J Clin Oncol. 2011;29:3852–3861.
   PubMed Web of Science ®Google Scholar
• Northcott PA, Lee C, Zichner T, et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature. 2014;511:428–434.
   PubMed Web of Science ®Google Scholar
• Von Bueren AO, Kortmann RD, Von Hoff K, et al. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. J Clin Oncol. 2016;34:4151–4160.
   PubMed Web of Science ®Google Scholar
• Clifford SC, Lannering B, Schwalbe EC, et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget. 2015;6:38827–38839.
   PubMed Web of Science ®Google Scholar
• Lafay-Cousin L, Smith A, Chi SN, et al. Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. Pediatr Blood Cancer. 2016;63:1527–1534.
   PubMed Web of Science ®Google Scholar
• Zapotocky M, Mata-Mbemba D, Sumerauer D, et al. Differential patterns of metastatic dissemination across medulloblastoma subgroups. J Neurosurg Pediatr. 2018;21:145–152.
   PubMed Web of Science ®Google Scholar
• Ramaswamy V, Remke M, Shih D, et al. Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent. Pediatr Blood Cancer. 2014;61:1190–1194.
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488:106–110.
   PubMed Web of Science ®Google Scholar
• Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488:100–105.
   PubMed Web of Science ®Google Scholar
• Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488:43–48.
   PubMed Web of Science ®Google Scholar
• Korshunov A, Remke M, Kool M, et al. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathol. 2012;123:515–527.
   PubMed Web of Science ®Google Scholar
• Lin CY, Erkek S, Tong Y, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature. 2016;530:57–62.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. 2016;17:484–495.
   PubMed Web of Science ®Google Scholar
• Kool M, Koster J, Bunt J, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS ONE. 2008;3:e3088.
   PubMed Web of Science ®Google Scholar
• Cho Y-J, Tsherniak A, Tamayo P, et al. Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. J Clin Oncol. 2011;29:1424–1430.
   PubMed Web of Science ®Google Scholar
• Capper D, Jones DTW, Sill M, et al. DNA methylation-based classification of central nervous system tumours. Nature. 2018;555:469–474.
   PubMed Web of Science ®Google Scholar
• Paterson E, Cerebellar Medulloblastoma: RFF. Treatment by Irradiation of the Whole Central Nervous System. Acta Radiol. 1953;39:323–336.
   PubMed Web of Science ®Google Scholar
• Mulhern RK, Merchant TE, Gajjar A, et al. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 2004;5:399–408.
   PubMed Web of Science ®Google Scholar
• Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328:1725–1731.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978–986.
   PubMed Web of Science ®Google Scholar
• Geyer JR, Sposto R, Jennings M, et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children’s Cancer Group. J Clin Oncol. 2005;23:7621–7631.
   PubMed Web of Science ®Google Scholar
• Grundy RG, Wilne SH, Robinson KJ, et al. Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG/SIOP CNS 9204 trial. Eur J Cancer. 2010;46:120–133.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Cohen B, Finlay J, et al. Medulloblastoma in young children. Pediatr Blood Cancer. 2010;54:635–637.
   PubMed Web of Science ®Google Scholar
• Cohen BH, Geyer JR, Miller DC, et al. Pilot Study of Intensive Chemotherapy With Peripheral Hematopoietic Cell Support for Children Less Than 3 Years of Age With Malignant Brain Tumors, the CCG-99703 Phase I/II Study. A Report From the Children’s Oncology Group. Pediatr Neurol. 2015;53:31–46.
   PubMed Web of Science ®Google Scholar
• Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol. 2004;22:4881–4887.
   PubMed Web of Science ®Google Scholar
• Muller K, Mynarek M, Zwiener I, et al. Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma–an experience from the HIT-REZ 1997 & 2005 studies. Int J Radiat Oncol Biol Phys. 2014;88:1019–1024.
   PubMed Web of Science ®Google Scholar
• Garre ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome–a new clinical perspective. Clin Cancer Res. 2009;15:2463–2471.
   PubMed Web of Science ®Google Scholar
• Jakacki RI, Burger PC, Zhou T, et al. Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children’s Oncology Group Phase I/II Study. J Clin Oncol. 2012;30:2648–2653.
   PubMed Web of Science ®Google Scholar
• Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013;31:2936–2941.
   PubMed Web of Science ®Google Scholar
• Gandola L, Massimino M, Cefalo G, et al. Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. J Clin Oncol. 2008;27:566–571.
   PubMed Web of Science ®Google Scholar
• Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children’s Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17:832–845.
   PubMed Web of Science ®Google Scholar
• Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94:552–560.
   PubMed Web of Science ®Google Scholar
• Morfouace M, Shelat A, Jacus M, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell. 2014;25:516–529.
   PubMed Web of Science ®Google Scholar
• Phoenix TN, Patmore DM, Boop S, et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell. 2016;29:508–522.
   PubMed Web of Science ®Google Scholar
• Pizer B, Donachie PH, Robinson K, et al. Treatment of recurrent central nervous system primitive neuroectodermal tumours in children and adolescents: results of a Children’s Cancer and Leukaemia Group study. Eur J Cancer. 2011;47:1389–1397.
   PubMed Web of Science ®Google Scholar
• Bakst RL, Dunkel IJ, Gilheeney S, et al. Reirradiation for recurrent medulloblastoma. Cancer. 2011;117:4977–4982.
   PubMed Web of Science ®Google Scholar
• Massimino M, Cohen KJ, Finlay JL. Is there a role for myeloablative chemotherapy with autologous hematopoietic cell rescue in the management of childhood high-grade astrocytomas? Pediatr Blood Cancer. 2010;54:641–643.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Pizer B. Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors. Pediatr Blood Cancer. 2010;54:649–651.
   PubMed Web of Science ®Google Scholar
• Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2014;61:636–642.
   PubMed Web of Science ®Google Scholar
• Peyrl A, Chocholous M, Kieran MW, et al. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatr Blood Cancer. 2012;59:511–517.
   PubMed Web of Science ®Google Scholar
• Rutkowski S, Von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 2010;28:4961–4968.
   PubMed Web of Science ®Google Scholar
• Morrissy AS, Garzia L, Shih DJ, et al. Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016;529:351–357.
   PubMed Web of Science ®Google Scholar
• Kramer K, Pandit-Taskar N, Humm JL, et al. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatr Blood Cancer. 2018;65:e26754.
   Web of Science ®Google Scholar
• Gholamin S, Mitra SS, Feroze AH, et al. Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9:eaaf2968.
   Web of Science ®Google Scholar
• Nair SK, Driscoll T, Boczkowski D, et al. Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. J Neurooncol. 2015;125:65–74.
   PubMed Web of Science ®Google Scholar
• Nellan A, Rota C, Majzner R, et al. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer. 2018;6:30.
   PubMed Web of Science ®Google Scholar
• Lastowska M, Trubicka J, Niemira M, et al. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients. Am J Surg Pathol. 2017;41:781–787.
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Fenchel K, Uciechowski P, et al. Targeting Developmental Pathways: the Achilles Heel of Cancer? Oncology. 2017;93:213–223.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–1178.
   PubMed Web of Science ®Google Scholar
• Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572–574.
   PubMed Web of Science ®Google Scholar
• Ardecky R, Magnuson GK, Zou J, et al. Small-molecule antagonists of Gli function. In: Probe Reports from the NIH Molecular Libraries Program. National Center for Biotechnology Information (US), Bethesda. MD; 2010. PMID: 24049850.
   Google Scholar
• Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23–34.
   PubMed Web of Science ®Google Scholar
• Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014;20:732–740.
   PubMed Web of Science ®Google Scholar
• Gustafson WC, Meyerowitz JG, Nekritz EA, et al. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 2014;26:414–427.
   PubMed Web of Science ®Google Scholar
• Zhukova N, Ramaswamy V, Remke M, et al. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications. 2014;2:174.
   PubMed Web of Science ®Google Scholar
• Pei Y, Liu KW, Wang J, et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. Cancer Cell. 2016;29:311–323.
   PubMed Web of Science ®Google Scholar
• Bandopadhayay P, Bergthold G, Nguyen B, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20:912–925.
   PubMed Web of Science ®Google Scholar
• Diaz RJ, Golbourn B, Faria C, et al. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget. 2015;6:3359–3374.
   PubMedGoogle Scholar
• Garzia L, Kijima N, Morrissy AS, et al. A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell. 2018;172:1050–62 e1014.
   PubMed Web of Science ®Google Scholar
• Dietl S, Schwinn S, Dietl S, et al. MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. BMC Cancer. 2016;16:115.
   PubMed Web of Science ®Google Scholar
• Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997;277:1109–1113.
   PubMed Web of Science ®Google Scholar
• Pazzaglia S, Mancuso M, Atkinson MJ, et al. High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice. Oncogene. 2002;21:7580–7584.
   PubMed Web of Science ®Google Scholar
• Uziel T, Zindy F, Sherr CJ, et al. The CDK inhibitor p18Ink4c is a tumor suppressor in medulloblastoma. Cc. 2006;5:363–365.
   Web of Science ®Google Scholar
• Ayrault O, Zindy F, Rehg J, et al. Two tumor suppressors, p27Kip1 and patched-1, collaborate to prevent medulloblastoma. Mol Cancer Res. 2009;7:33–40.
   PubMed Web of Science ®Google Scholar
• Schüller U, Heine VM, Mao J, et al. Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma. Cancer Cell. 2008;14:123–134.
   PubMed Web of Science ®Google Scholar
• Briggs KJ, Corcoran-Schwartz IM, Zhang W, et al. Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev. 2008;22:770–785.
   PubMed Web of Science ®Google Scholar
• Wu X, Northcott PA, Dubuc A, et al. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature. 2012;482:529–533.
   PubMed Web of Science ®Google Scholar
• Collier LS, Carlson CM, Ravimohan S, et al. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature. 2005;436:272–276.
   PubMed Web of Science ®Google Scholar
• Dupuy AJ, Akagi K, Largaespada DA, et al. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system. Nature. 2005;436:221–226.
   PubMed Web of Science ®Google Scholar
• Genovesi LA, Ng CG, Davis MJ, et al. Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A. 2013;110:E4325–34.
   PubMed Web of Science ®Google Scholar
• Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev. 2003;13:34–42.
   PubMed Web of Science ®Google Scholar
• Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001;61:513–516.
   PubMed Web of Science ®Google Scholar
• Rausch T, Jones DT, Zapatka M, et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell. 2012;148:59–71.
   PubMed Web of Science ®Google Scholar
• Lee Y, Kawagoe R, Sasai K, et al. Loss of suppressor-of-fused function promotes tumorigenesis. Oncogene. 2007;26:6442–6447.
   PubMed Web of Science ®Google Scholar
• Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31:306–310.
   PubMed Web of Science ®Google Scholar
• Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res. 2008;68:1768–1776.
   PubMed Web of Science ®Google Scholar
• Dey J, Dubuc AM, Pedro KD, et al. MyoD is a tumor suppressor gene in medulloblastoma. Cancer Res. 2013;73:6828–6837.
   PubMedGoogle Scholar
• Dey J, Ditzler S, Knoblaugh SE, et al. A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol Cell Biol. 2012;32:4104–4115.
   PubMed Web of Science ®Google Scholar
• Rao G, Pedone CA, Valle LD, et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004;23:6156–6162.
   PubMed Web of Science ®Google Scholar
• Doucette TA, Yang Y, Pedone C, et al. WIP1 enhances tumor formation in a sonic hedgehog-dependent model of medulloblastoma. Neurosurgery. 2012;70:1003–1010, discussion 1010
   PubMed Web of Science ®Google Scholar
• Binning MJ, Niazi T, Ca P, et al. Hepatocyte growth factor and sonic Hedgehog expression in cerebellar neural progenitor cells costimulate medulloblastoma initiation and growth. Cancer Res. 2008;68:7838–7845.
   PubMed Web of Science ®Google Scholar
• Browd SR, Kenney AM, Gottfried ON, et al. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006;66:2666–2672.
   PubMed Web of Science ®Google Scholar
• Fults DW. Modeling medulloblastoma with genetically engineered mice. Neurosurg Focus. 2005;19:E7.
   PubMedGoogle Scholar
• Mumert M, Dubuc A, Wu X, et al. Functional Genomics Identifies Drivers of Medulloblastoma Dissemination. Cancer Res. 2012;72:4944–4953.
   PubMed Web of Science ®Google Scholar
• Poschl J, Stark S, Neumann P, et al. Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathol. 2014;128:123–136.
   PubMed Web of Science ®Google Scholar
• Pei Y, Moore CE, Wang J, et al. An Animal Model of MYC-Driven Medulloblastoma. Cancer Cell. 2012;21:155–167.
   PubMed Web of Science ®Google Scholar
• Kawauchi D, Robinson G, Uziel T, et al. A mouse model of the most aggressive subgroup of human medulloblastoma. Cancer Cell. 2012;21:168–180.
   PubMed Web of Science ®Google Scholar
• Hanaford AR, Archer TC, Price A, et al. DiSCoVERing Innovative Therapies for Rare Tumors: combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016;22:3903–3914.
   PubMed Web of Science ®Google Scholar
• Vo BT, Li C, Morgan MA, et al. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports. 2017;18:2907–2917.
   PubMed Web of Science ®Google Scholar
• Kawauchi D, Ogg RJ, Liu L, et al. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene. 2017.
   PubMed Web of Science ®Google Scholar
• Jenkins NC, Rao G, Eberhart CG, et al. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice. J Neurooncol. 2016;126:415–424.
   PubMed Web of Science ®Google Scholar
• Swartling FJ, Savov V, Persson AI, et al. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC. Cancer Cell. 2012;21:601–613.
   PubMed Web of Science ®Google Scholar
• Swartling FJ, Grimmer MR, Hackett CS, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev. 2010;24:1059–1072.
   PubMed Web of Science ®Google Scholar